The latest price target for Crinetics Pharmaceuticals (NASDAQ:CRNX) was reported by Jefferies on January 22, 2025. The analyst firm set a price target for $55.00 expecting CRNX to rise to within 12 months (a possible 37.50% upside). 37 analyst firms have reported ratings in the last year.

The latest analyst rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) was provided by Jefferies, and Crinetics Pharmaceuticals upgraded their buy rating.

The last upgrade for Crinetics Pharmaceuticals Inc happened on January 22, 2025 when Jefferies raised their price target to $55. Jefferies previously had a hold for Crinetics Pharmaceuticals Inc.

There is no last downgrade for Crinetics Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crinetics Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crinetics Pharmaceuticals was filed on January 22, 2025 so you should expect the next rating to be made available sometime around January 22, 2026.

While ratings are subjective and will change, the latest Crinetics Pharmaceuticals (CRNX) rating was a upgraded with a price target of $0.00 to $55.00. The current price Crinetics Pharmaceuticals (CRNX) is trading at is $40.00, which is within the analyst’s predicted range.